Latest Organic chemistry Stories
- Additional Phase 3 analysis show significantly faster reduction in pain and fewer patients with oxygen desaturation events for Sufentanil NanoTab PCA System than IV PCA with morphine - REDWOOD CITY, Calif., May 2, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported additional...
The Rottenstein Law Group, which represents clients with claims for injuries and birth defects allegedly caused by selective serotonin reuptake inhibitor antidepressants (SSRIs) including Zoloft, is helping to publicize the results of a study showing an increased mortality rate during the perioperative period for patients who are on an SSRI. (PRWEB) May 01, 2013 The Rottenstein Law Group, which represents clients with claims for injuries and birth defects allegedly caused by selective...
Researchers from CHOP, Penn find better outcomes for efavirenz over nevirapine in children over age 3 in low-resource settings Researchers from The Children's Hospital of Philadelphia and the Perelman School of Medicine at The University of Pennsylvania, along with colleagues at the Botswana-Baylor Children's Clinical Centre of Excellence, conducted the first large-scale comparison of first-line treatments for HIV-positive children, finding that initial treatment with efavirenz was more...
Surveyed U.S. Psychiatrists Expect to Prescribe Edivoxetine to 25 Percent of Their Patients with Treatment-Resistant Depression, According to a New Report from Decision Resources BURLINGTON, Mass., May 1, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a greater effect on depressive symptoms than current treatments is one of the greatest unmet needs in patients with...
NEWARK, Calif., May 1, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release first quarter fiscal year 2013 financial results after the market closes on Wednesday, May 8, 2013. The Company will host a conference call beginning at 4:30 pm Eastern time, 1:30 pm California time to discuss its results. Participants can access the call by dialing 877-317-6789 (United States) or 412-317-6789 (international). The conference call will also be available via a...
RIDGEFIELD, Conn., April 30, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced three important updates to the U.S. prescribing information for PRADAXA, an oral anticoagulant (OAC) indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). The PRADAXA label now carries a Boxed Warning, similar to the Boxed Warnings in the labels of other new OACs, to advise patients that discontinuing treatment...
Over 1,000 chronic pain patients currently on opioids surveyed to understand and quantify the potential market opportunity for Collegium's DETERx® based product candidates CANTON, Mass., April 30, 2013 /PRNewswire/ -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced the completion of a 1,021 patient survey, which consisted of patients with chronic pain currently on opioid...
NEW YORK, April 29, 2013 /PRNewswire/ -- Commenting on a $6.5 million dollar verdict reached this past Friday in a Los Angeles courtroom against Takeda Pharmaceuticals for injuries arising from the plaintiffs' ingestion of Takeda's blockbuster selling diabetes drug, Actos®, Napoli Bern Ripka Shkolnik, LLP Senior Partner Hunter Shkolnik described the verdict as "a disaster for Takeda". In the California trial, a jury found that in marketing Actos®, which has been linked to bladder...
Drug manufacturer did not submit suitable data in its dossier The fixed combination of the drugs saxagliptin and metformin (Komboglyze®) has been approved in Germany since November 2011 for the treatment of type 2 diabetes mellitus. In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products” (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this fixed combination product offers an added benefit...
Focus on Acute Pain and Uremic Pruritus SHELTON, Conn. and OSAKA, Japan, April 29, 2013 /PRNewswire/ -- Cara Therapeutics, Inc. and Maruishi Pharmaceutical Company, Ltd. (Maruishi) today announced that they have entered into a License Agreement providing Maruishi with exclusive rights to develop, manufacture and commercialize Cara's lead analgesic drug candidate, CR845, for acute pain and uremic pruritus in Japan. CR845 is a highly selective, peptide-based, peripherally-restricted...
Latest Organic chemistry Reference Libraries
Organometallics is a peer-reviewed scientific journal published by the American Chemical Society. As of May 2012, the editor-in-chief is John A. Gladysz. Organometallics publishes records in one of the most active fields for organometallic, inorganic, organic, and materials chemists. Articles, communications, mini-reviews, and notes detail the synthesis, structure, bonding, chemical reactivity and reaction mechanisms, and applications of organometallic and organometalloidal compounds....
Synthetic Metals is a peer-reviewed scientific journal published by Elsevier. It covers all aspects of electronic polymers and electronic molecular materials. It is an international medium for the rapid publication of original research papers, short communications and subject reviews dealing with research on and applications of electronic polymers and electronic molecular materials including novel carbon architectures. Original manuscripts on chemical, electrochemical, electrical, photonic...
